threonine kinase GSK-3␤ to produce a conditional loss-
knockin mice, GSK-3␤FRB* protein levels and activity as C20-MaRap on either substrate. The disruption of the rigid triene bond region from C17 to C22 may inare rapidly and reversibly controlled using C20-MaRap and a competitor molecule. Our results provide a crease the flexibility of C20-MaRap, improving its ability to fit within the mutant FRB* binding pocket. method for regulating the products of an endogenous murine gene. We expressed GSK-3␤ fused to FRB* with the intention of conditionally regulating GSK-3␤ using an inducible form a composite surface that interacts with and inhibits FKBP12-rapamycin-associated protein (FRAP) (Brown dimerization system that will be described elsewhere. However, we found that GSK-3␤FRB* was expressed at et al. 
FRB* Directs Fusion Proteins to Degradation
. Despite their dissimilarities in molecular weight, subcellular site of come these undesired teratogenic effects of rapamycin, chemically modified rapamycin analogs (or rapalogues) action, and structure, the levels of each FRB* fusion protein increased between 3.5-and 100-fold upon drug have been synthesized that do not bind the wild-type FRB domain (Liberles et al., 1997). These rapalogues, addition (data not shown). These results suggest that FRB* has the general property of conferring reversible such as C16-methallylrapamycin (C16-MaRap), contain bulky chemical substitutions, "bumps," at the FRB bindinstability to fusion proteins. To understand the minimal requirements for condiing interface of rapamycin. A compensatory "hole" created at the rapamycin binding site of certain FRB point tional protein stability, we repeated the assay with GSK-3␤FRB#. FRB# contains only the T2098L substitution mutants restores binding specificity to these modified rapalogues. FRB* is one such FRB mutant that contains present in FRB* and is otherwise wild-type. GSK-3␤FRB#, like GSK-3␤FRB*, is rapidly degraded while three point mutations: K2095P, T2098L, and W2101F (Liberles et al., 1997).
being stabilized by rapamycin (Figure 2A ). From these data, we conclude that the T2098L mutation may be We modified the published methods for the synthesis of C16-MaRap (Liberles et al., 1997) to isolate both C16 the major cause of FRB*-mediated instability. As this mutation introduces a hydrophobic residue in a region and C20-methallylrapamycin (C20-MaRap) ( Figure 1A ) (for details see http://crablab.stanford.edu/synthesisofmarap. that would be otherwise surface exposed (Choi et al., 1996), proteins fused to FRB* or FRB# may become htm). We tested the ability of both of these bumped rapalogues to activate transcription by recruitment of partially unfolded, leading to the destabilization and eventual degradation of the fusion protein. chimeric transcriptional activation and DNA binding domains Rivera et al., 1996) . In these To further characterize FRB*-mediated destabilization, we expressed each of FRB, FRB*, and FRB# as assays, FKBP fused to the GAL4 DNA binding domain and FRB or FRB* fused to the activation domain of VP16 GST fusions in E. coli. The thermal stability of the purified fusion proteins was determined using circular dichroism were cotransfected into COS-1 cells along with a GAL4-dependent secreted alkaline phosphatase (SeAP) respectroscopy (CD). Freshly isolated GST-FRB variants did not unfold or aggregate at 4ЊC as determined by the porter plasmid. Addition of rapamycin or rapalogues caused heterodimerization of the fusions and activation characteristic appearance of the CD spectra ( Figure 2C lower than GST fused to wild-type FRB ( Figure 2D ). was constructed with a neomycin resistance selection cassette flanked by loxP sites placed in the last intron of These results are consistent with the model that the T2098L mutation destabilizes FRB structure. This insta-GSK-3␤ and an FRB*HA sequence placed immediately before the stop codon of GSK-3␤ ( Figure 3A ). Homolobility is subsequently transmitted to the entire fusion protein and likely triggers the destruction of FRB* or gous recombination in ES cells was used to target this construct to the endogenous GSK-3␤ locus. Mice were FRB# fusion proteins in cells.
The preceding results demonstrate that FRB* confers derived from correctly targeted cells, and the neomycin resistance cassette was removed by crossing these two characteristics to fusion proteins: it provides the ability to dimerize to FKBP12 in the presence of the mice with mice expressing the Cre recombinase under the ubiquitous ␤-actin promoter (Lewandoski et al., nontoxic rapalogue, C20-MaRap, and it causes the protein to be destabilized and degraded. Importantly, this 1997). As a result, the only genomic changes in the derived mouse line were a single loxP site in the last directed degradation is blocked by dimerization to FKBP12 using C20-MaRap. Dimerization may "lock" intron of GSK-3␤ and the FRB*HA sequence inserted at the extreme 3Ј end of the GSK-3␤ coding region. This FRB* in a folded state, energetically stabilized by interactions with FKBP12 and the rapalogue ( Figure 2E) . design was employed to ensure minimal disruption of GSK-3␤ regulatory elements. Indeed, GSK-3␤ FRB* mRNA These dual features of FRB* suggested a general means of producing conditional alleles based on small molewas present at normal levels (data not shown). Furthermore, a C-terminal FRB* fusion was chosen to prevent cule-induced stabilization.
interference with the N-terminal serine 9 phosphorylation site of GSK-3␤. Additionally, the crystal structure 
dent transcription in transient tranfection assays in Jur-
the expression of GSK-3␤FRB* in heterozygous mice and found GSK-3␤FRB* levels to be greatly reduced kat T cells and could still be phosphorylated at serine 9 (data not shown).
relative to wild-type protein in all tissues examined. Heart and thymus expression levels are shown in Figure  Although 
GSK-3␤
ϩ/FRB* mice were viable and fertile, most GSK-3␤ FRB*/FRB* mice died immediately following 3B. This result is consistent with the FRB*-directed degradation of GSK-3␤FRB* seen in transfection experibirth, being present at normal Mendelian ratios at embryonic day E18.5 (K.S. and G.R.C., unpublished data). ments and with the severe loss-of-function phenotype of GSK-3␤ FRB*/FRB* mice. Although there were no obvious defects to explain this phenotype, the mice did exhibit a complete cleft of the secondary palate (K.S. and G.R.C., unpublished data).
GSK-3␤FRB* Is Inducibly and Reversibly Stabilized in MEFs As a result, the occasional homozygous pup that did not die immediately after birth failed to suckle and died We prepared MEFs containing the GSK-3␤ FRB* allele. Heterozygous cells expressed greatly reduced levels of within 12 hr of birth. In our laboratory, this phenotype is indistinguishable from that of GSK-3␤ KO/KO and GSK-GSK-3␤FRB*, consistent with its low level of expression in adult tissues. GSK-3␤FRB* was degraded at an en-3␤ KO/FRB* mice on outbred backgrounds. We examined hanced rate relative to the wild-type GSK-3␤ protein of blocking an FRB*-mediated effect, rather than a dominant effect of recruiting FKBP12. However, as expected, observed when translation was blocked with CHX (Figure 3C) . A 36 hr treatment with C20-MaRap restored the stabilization did require FKBP12 binding, as indicated by the complete loss of C20-MaRap-induced sta-GSK-3␤FRB* levels in GSK-3␤ FRB*/FRB* cells to those of GSK-3␤ in wild-type MEFs ( Figure 3D ). Rapamycin probilization in fibroblasts that are doubly homozygous for GSK-3␤ FRB* and an FKBP12 allele, FKBP12
IM
, that lacks duced an identical effect (data not shown), and neither drug had an effect on wild-type GSK-3␤, ␤-catenin, or detectable FKBP12 expression ( Figure 3F ). FK506 is a small molecule that binds to FKBP12 with HSP-90 expression. We performed a time course of C20-MaRap treatment on heterozygous MEFs to study the high affinity to form a complex that interacts with and inhibits the phosphatase calcineurin (Liu et al., 1991). We rate of inducible stabilization and found that stabilization was complete in approximately 24 hr with half maximal reasoned that FK506 could be used to reverse inducible stabilization by competing with C20-MaRap for binding stabilization observed at 8-12 hr ( Figure 3E ). Importantly, the levels did not increase beyond those of the to FKBP12. We stabilized GSK-3␤FRB* in heterozygous MEFs and then treated the cells across a time course wild-type protein, suggesting that stabilization is a result with a derivative of FK506 called FK506M that does not thase, but not into the GSA peptide, which contains a serine-alanine mutation at the GSK-3 phosphorylation bind calcineurin but retains the ability to bind FKBP12 (Spencer et al., 1993) . Following FK506M treatment, site ( Figure 5A ). Destabilized GSK-3␤FRB* isolated from untreated GSK-3␤ FRB*/FRB* MEFs contained less than 10% GSK-3␤FRB* was rapidly degraded, returning to steadystate low levels in less than 9 hr ( Figure 4A) . Inducible of normal GSK-3␤ kinase activity. However, GSK-3␤FRB* immunoprecipitated from C20-MaRap-treated stabilization is therefore readily reversible. The use of different relative concentrations of FK506M to C20-GSK-3␤ FRB*/FRB* cells had an over 7-fold increase in activity and approximately 60% of the activity of wild-type MaRap produced a gradient of steady-state GSK-3␤FRB* levels ( Figure 4B ). As such, the ratio of the two cells. Furthermore, the stabilized GSK-3␤FRB* remained bound to FKBP12 during the kinase assay, indicating drugs can be used to titer GSK-3␤FRB* activity and produce an allelic series.
that FKBP12-C20-MaRap binding does not inhibit GSK-3␤'s activity or substrate access ( Figure 5B ). GSK-3␤FRB* stabilized in GSK-3␤ FRB*/FRB* MEFs showed a sim-FRB*-Mediated Degradation Is Directed by the Proteasome ilar activity to that present in identically prepared and treated GSK-3␤ ϩ/KO MEFs ( Figure 5A ). Since GSK-3␤
To determine the mechanism underlying FRB*-mediated degradation, we tested whether degradation occurred cells and mice appear completely normal, we anticipate that inducible stabilization could recover sufficient levin the presence of specific protease inhibitors. GSK-3␤FRB* was stabilized to normal levels in heterozygous els of GSK-3␤ activity to restore the kinase's normal functions. MEFs before the stabilization was reversed by the addition of FK506 to the culture media. When the stabilization Because GSK-3␤ regulates a wide variety of signaling pathways, transcription factors, and cell cycle regulawas reversed in the presence of lactacystin ( Figure 4C ) or MG132 (data now shown), two proteasomal inhibitors, tors, we expected to find multiple cellular phenotypes in GSK-3␤ FRB*/FRB* fibroblasts that we could study using GSK-3␤FRB* remained largely stabilized. E-64D, an inhibitor of lysosomal cysteine proteases, did not protect inducible stabilization. However, as reported with GSK-3␤ KO/KO MEFs (Hoeflich et al., 2000) , we found no defects GSK-3␤FRB* from degradation. Therefore, FRB*-mediated destabilization results, at least in part, in proteasoin cell growth or ␤-catenin levels in the GSK-3␤ FRB*/FRB* MEFs (data not shown). Additionally, we found no defect mal degradation. However, we did not detect ubiquitination of GSK-3␤FRB* (data not shown), indicating that its in NF-AT activity or in the rate of endogenous NF-ATc1 rephosphorylation following pharmacologic calcineurin proteasomal targeting may be ubiquitin independent or that the life of ubiquitinated intermediates is very short. inhibition in GSK-3␤ FRB*/FRB* or GSK-3␤ KO/KO MEFs (data not shown). Furthermore, unlike Hoeflich et al. (2000), we did not detect a significant defect in NF-B signaling GSK-3␤ Activity Is Restored by Inducible Stabilization We performed GSK-3␤ immunoprecipitation-kinase in response to TNF-␣, or enhanced cell death in response to TNF-␣ and CHX (data not shown). This disassays on fibroblast lysates to test whether inducible stabilization restored GSK-3␤ activity. Immunoprecipicrepancy may be due to different methods used during fibroblast preparation. The lack of phenotypes is likely tated wild-type GSK-3␤ effectively incorporated radiolabeled ATP into the GSP peptide from glycogen syndue to the presence of functionally redundant GSK-3␣. The amino acid sequence of GSK-3␣ is highly similar to MaRap-treated mothers ( Figure 5C ). Full stabilization was not observed, likely because the concentrations GSK-3␤ (82% identity), and GSK-3␣ can replace GSK-3␤ for most of its biological functions that have been of C20-MaRap remained low in embryos (Ͻ25 nM), as measured by organic extraction and biological activity tested. Therefore, conditional biological studies of GSK-3 signaling functions in fibroblasts and probably other cell testing using the transcriptional switch assay (data not shown). New rapalogues that combine both the ability types using GSK-3␤FRB*-inducible stabilization will require the background removal of GSK-3␣.
of C20-MaRap to bind FRB* and the excellent pharmacokinetics of rapamycin will be required to provide more effective stabilization in vivo.
GSK-3␤FRB* Can Be Stabilized In Utero
To be used as a conditional allele system in whole animal developmental studies, we must be able to deliver C20- . Unfortunately, such approaches have not been previously validated in a mouse system. An tion course consisted of three intraperitoneal (i.p.) injections repeated every 12 hr, followed by the harvesting ideal system for making conditional alleles in mice could be broadly and readily applicable to many targets and of the embryos at E11.5. Neither the mother nor the embryos were overtly affected by this drug course. In would allow the rapid and reversible regulation of the target while avoiding nonspecific background effects. contrast, rapamycin, similarly injected at 10 mg/kg/day, produced "flat top" embryos due to a failure of telecephToward this goal, we report the development of a technology that allows the inducible stabilization of FRB* alon outgrowth, demonstrating the necessity of using nonteratogenic rapalogues. Protein lysates were prefusion proteins using a chemical inducer of dimerization. We apply this method to endogenous murine GSK-3␤, pared from the C20-MaRap-treated embryos and from stage-matched embryos from a mock-injected mother producing a chemically sensitive allele of an endogenous mouse gene. By combining gene targeting, which and analyzed by Western blotting. GSK-3␤FRB* protein levels were partially restored in embryos from the C20-is highly specific and can be used on nearly any mouse gene with small molecules which provide rapid proteinto developmental or target validation studies. Most level regulation, this technology fulfills many of the charphysiological events, including cell cycle progression, acteristics of an ideal conditional allele system. apoptosis, axonal outgrowth, synapse formation, and Conditional protein alleles are particularly suited for lymphocyte activation, are also dynamic and would developmental studies because existing gene deletion therefore benefit from protein targeting. Furthermore, technologies do not provide sufficient temporal control many of these processes can be readily studied in cell, to dissect separate roles of a gene during a series of tissue, or organ culture systems, where we can effecrapid development events. Inducible stabilization of tively deliver C20-MaRap. Importantly, conditional pro-GSK-3␤FRB* is complete within 24 hr of C20-MaRap tein alleles can be used to minimize or define secondary treatment in MEFs (Figure 3E glycol 400, 17% polyoxyethylene sorbitan monooleate, and 10% and anti-HSP-70 antibody (1:1000) were purchased from Santa Cruz DMA to a final concentration of 100 mg/kg. One hundred microliters Biotechnology. The anti-BRG1 antibody (1:1000) was previously dewas immediately injected intraperitoneally to pregnant females with scribed (Khavari et al., 1993) . The anti-FRB antibody was prepared injections repeated twice more at 12 hr intervals to E11.5 when mice in our laboratory using recombinant GST-FRB as an antigen. In all were sacrificed, and embryos and organs were dissected and frozen cases, Western blots were incubated overnight with the appropriate in N 2(l) . Tissues anterior to the embryonic forelimbs of individual primary antibodies in TBST (10 mM Tris 8.0, 150 mM NaCl, 0.1% embryos were used for preparation of protein extracts with the Tween 20) containing 10% dry milk and then washed three times remainder used to determine the concentration of drug and for genowith TBST. The blots were subsequently incubated for 30 min with typing. HRP-conjugated secondary antibodies from Jackson Immunoresearch, washed three more times with TBST, and then developed
Discussion

